Prostate-specific antigen (PSA) complexed to α1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL

BJU International

Volumn 95, Issue 6, 2005, Pages 761-765

  Kobayashi, Takashi ^a   Kamoto, Toshiyuki ^b   Nishizawa, Koji ^a   Mitsumori, Kenji ^a   Ogura, Keiji ^a   Ide, Yoshihiro ^a  

^a HAMAMATSU ROSAI HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnosis; Prostatic adenocarcinoma; PSA ACT; Receiver operating characteristic analysis; Unnecessary biopsy

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; ALPHA 1-ANTICHYMOTRYPSIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERINE PROTEINASE INHIBITORS;

EID: 17444416413     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05396.x     Document Type: Conference Paper

References (21)

1. Berger AP, Volgger H, Rogatsch H et al. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens. Prostate 2002; 53: 241-5
2. Kubota Y, Ito K, Imai K, Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002; 50: 262-9
3. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-63
4. Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
5. Finne P, Zhang WM, Auvinen A et al. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. J Urol 2000; 164: 1956-60
6. Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
7. Jung K, Elgeti U, Lein M et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA. Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55-62
8. Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001; 165: 1549-53
9. Saika T, Tsushima T, Nasu Y et al. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002; 94: 1685-91
10. Kobayashi T, Kamoto T, Isogawa Y et al. Ratio of prostate specific antigen minor molecular forms to total prostate specific antigen is constant regardless of the pathological condition of the prostate. J Urol 2003; 169: 121-4
11. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1- antichymotrypsin complex together with free or total PSA. Clin Chem 2003; 49: 97-103
12. Kuriyama M, Abrahamsson PA, Imai K et al. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases. Scand J Urol Nephrol 2001; 35: 5-10
13. Stamey TA. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology 1995; 45: 173-84
14. Jung K, Brux B, Lein M et al. Determination of alpha1-antichymotrypsin- PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology 1999; 53: 1160-7
15. Bjork T, Piironen T, Pettersson K et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996; 48: 882-8
16. Miyake H, Hara S, Nomi M, Arakawa S, Kamidono S, Hara I. Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters. Int J Urol 2001; 8: 589-93
17. Okihara K, Cheli CD, Partin AW et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167: 2017-23
18. Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per milliliter. Urology 2002; 60: 31-5
19. Sokoll LJ, Chan DW, Mikolajczyk SD et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003; 61: 274-6
20. Parsons JK, Partin AW. Applying complexed prostate-specific antigen to clinical practice. Urology 2004; 63: 815-8
21. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304-10